Barclays raised the firm’s price target on Medtronic (MDT) to $120 from $118 and keeps an Overweight rating on the shares. The firm updated the company’s model to reflect the company’s Q4 dilution from the MiniMed initial public offering and noncash charges related to the early approval of MiniMed’s Flex pump.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- MiniMed initiated with a Buy at BofA
- Medtronic announces FDA clearance of Stealth AXiS surgical system
- Medtronic: Temporary MiniMed Charge Leaves Multi‑Year Earnings Growth and Buy Thesis Intact
- Medtronic Cuts Fiscal 2026 EPS Outlook After MiniMed Charges
- Medtronic cuts FY26 EPS view to $5.50-$5.54 from $5.62-$5.66, consensus $5.64